Medha Baranwal

5 days ago | medicaldialogues.in | Medha Baranwal

Spain: In the phase III DELTA FORCE trial, delgocitinib cream demonstrated superior efficacy and a more favorable safety profile than oral alitretinoin for patients with severe chronic hand eczema. Fewer adverse events were reported in the delgocitinib group (49%) versus the alitretinoin group (76%), highlighting it as a promising alternative in a field with limited treatment options. The findings were published online in The Lancet on April 16, 2025.

5 days ago | medicaldialogues.in | Medha Baranwal

Italy: A recent meta-analysis published in the Head & Neck journal revealed that preoperative vitamin D supplementation significantly reduced the risk of postoperative hypocalcemia in patients undergoing total thyroidectomy. The analysis, which included data from eight clinical trials, found that vitamin D supplementation, with or without calcium, decreased the risk of hypocalcemia by 23%.

1 week ago | medicaldialogues.in | Medha Baranwal

USA: A new phase 3 clinical trial has found that a single multi-component mRNA vaccine targeting both seasonal influenza and COVID-19 is not only well-tolerated but also produces immune responses on par with, or even better than, current standard vaccinations in adults aged 50 years and older. The findings were published online in the Journal of the American Medical Association (JAMA) on May 7, 2025.

1 week ago | medicaldialogues.in | Medha Baranwal

Iran: A recent systematic review and meta-analysis has highlighted the alarming rise in myopia (short-sightedness) among children worldwide, attributing a significant part of this trend to the increasing use of digital devices. "Myopia affected 28.8% of children who used computers and video games, 35.4% of those who watched television, and 31.4% of smartphone users," the researchers reported.

1 week ago | medicaldialogues.in | Medha Baranwal

Egypt: A recent randomized clinical trial demonstrated that the intralesional measles, mumps, and rubella (MMR) vaccine is more effective than vitamin D3 in treating multiple warts, offering a promising alternative to traditional destructive therapies. In the study, published in the Indian Journal of Dermatology, Venereology and Leprology, 80.4% of patients in the MMR group (0.3 mL) achieved a complete response, compared to 66.1% in the vitamin D group (0.3 mL).